Quick Answer
BriaCell Therapeutics Corp. reported Operating Income Loss of -$27.20 million for the year ending 2025.
- BriaCell Therapeutics Corp. showed an increase of +18.4% in Operating Income Loss from 2024 to 2025.
- This data is from BriaCell Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on October 16, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2021: -$2.28 million | Q1 2022: -$3.65 million | Q2 2022: -$4.12 million | Q4 2022: -$5.40 million | Q1 2023: -$4.49 million | Q2 2023: -$5.68 million | Q4 2023: -$8.50 million | Q1 2024: -$9.83 million | Q2 2024: -$9.23 million | Q4 2024: -$5.15 million | Q1 2025: -$7.17 million | Q2 2025: -$6.33 million | Q4 2025: -$8.32 million.
- Over the full 5 years of available data (2021 to 2025), BriaCell Therapeutics Corp.'s Operating Income Loss has declined by 290.0%.
- Historical annual values: Fiscal year 2025: -$27.20 million | Fiscal year 2024: -$33.33 million | Fiscal year 2023: -$23.27 million | Fiscal year 2022: -$15.29 million | Fiscal year 2021: -$6.98 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: